GRI

GRI Bio, Inc. - Common Stock (GRI)

About GRI Bio, Inc. - Common Stock (GRI)

GRI Bio, Inc. engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.

Details

Daily high

$1.90

Daily low

$1.71

Price at open

52 Week High

$80.36

52 Week Low

$1.36

Market cap

3.5M

Dividend yield

0.00%

Volume

1,908

Avg. volume

384,113

P/E ratio

-.02

GRI Bio, Inc. - Common Stock News